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Cell line studies demonstrate that the PI3K/Akt pathway is upregulated in hormone-refractory prostate cancer (HRPC) and can result
in phosphorylation of the androgen receptor (AR). The current study therefore aims to establish if this has relevance to the
development of clinical HRPC. Immunohistochemistry was employed to investigate the expression and phosphorylation status of Akt
and AR in matched hormone-sensitive and -refractory prostate cancer tumours from 68 patients. In the hormone-refractory tissue,
only phosphorylated AR (pAR) was associated with shorter time to death from relapse (P¼0.003). However, when an increase in
expression in the transition from hormone-sensitive to -refractory prostate cancer was investigated, an increase in expression of PI3K
was associated with decreased time to biochemical relapse (P¼0.014), and an increase in expression of pAkt
473 and pAR
210 were
associated with decreased disease-specific survival (P¼0.0019 and 0.0015, respectively). Protein expression of pAkt
473 and pAR
210
also strongly correlated (Po0.001, c.c.¼0.711) in the hormone-refractory prostate tumours. These results provide evidence using
clinical specimens, that upregulation of the PI3K/Akt pathway is associated with phosphorylation of the AR during development of
HRPC, suggesting that this pathway could be a potential therapeutic target.
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Prostate cancer is an increasing heath-care problem, one out of six
UK men are diagnosed with this disease, which ranks second after
lung cancer as a cause of male cancer-specific mortality (Cancer
Research UK, 2004). Advanced prostate cancer treatment has
relied on hormone-deprivation therapy for the past 50 years.
Response rates are initially high (70–80%); however, almost all
patients relapse and develop hormone-refractory prostate cancer
(HRPC), resulting in increased morbidity and death (Cleeve and
Goad, 1995).
Amplification of the androgen receptor (AR) may explain
development of HRPC in 20–30% of patients (Edwards et al,
2001). In vitro studies demonstrate that Akt/protein kinase B
phosphorylates AR at serine residues (Ser
210 and Ser
790) resulting
in modulation of AR transcriptional activity (Lin et al, 2001, 2003)
and suggesting that AR phosphorylation might promote develop-
ment of HRPC. It has also been reported that activation of
phosphatidylinositol 3-OH kinase (PI3K)/Akt pathway can induce
expression of AR at the protein and mRNA level, again suggesting
that this pathway may be involved with hormone-refractory
disease (Yang et al, 2005). Akt is a downstream member of the
PI3K cascade, which plays an important role in cell growth, death,
adhesion and migration and is frequently activated in cancer cells
(Lin et al, 2003). Akt is activated when phosphorylated at
threonine 308 and subsequently serine 473. There are three
members of the Akt family, Akt1, -2 and -3, and evidence suggests
that the three isoforms of Akt have different roles in the
development of hormone-resistant breast cancer either via
interactions with the oestrogen receptor or via proteins involved
in proliferation and apoptosis, for example, mTOR and BAD
(Kirkegaard et al, 2005). Akt may play a similar role in the
development of HRPC (Liao et al, 2003). Cell line studies
demonstrate that low passage LNCaP cells (hormone-sensitive
prostate cancer cells) have low basal Akt activity, possibly due to
early-stage prostate cancer relying on hormones for growth and
survival. However, during hormone ablation or antihormone
treatment, LNCaP cells undergo growth arrest and apoptosis,
and Akt activity is upregulated (more than 20-fold higher),
resulting in stimulation of cell growth, compensating for the
effects of androgen withdrawal (Gao et al, 2003). Data from these
experiments suggest that Akt signals for cell growth and survival at
low levels of androgen, and therefore may promote development of
HRPC (Ghosh et al, 2003; Lin et al, 2003). This is supported by a
report that demonstrates that upregulation of the PI3K cascade
allows cells to grow in the presence of antiandrogens and
contributes to failure of endocrine therapy (Murillo et al, 2001).
A recent review suggests that the PI3K/Akt pathway is a possible
therapeutic target for treatment of prostate cancer (Pommery and
Henichart, 2005). Prostate tumours are reported to have sig-
nificantly higher Akt expression than BPH (Liao et al, 2003), and
only 10% of well-differentiated prostate tumours strongly express
pAkt compared to 92% of poorly differentiated tumours (Malik
et al, 2002; Ayala et al, 2003; Ghosh et al, 2003). Akt1 and Akt2
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sexpression in hormone-sensitive tumours have been associated
with shorter time to biochemical relapse; however, no association
was reported with the activated forms or with survival (Le Page
et al, 2006). However to our knowledge, this is the first study to
conduct a comprehensive investigation into the changes that occur
to multiple members of the pathway in the transition from clinical
hormone-sensitive to -refractory prostate cancer, and in particular,
to test if phosphorylation of AR is associated with patient outcome
measures.
MATERIALS AND METHODS
Patient
Sixty-eight patients with matched hormone-sensitive and -
refractory tumour pairs were retrospectively selected for analysis.
All tumours had patient identification removed, including block
number and hospital number and were coded to make the database
anonymous. Ethical approval was obtained from the Multicentre
Research Ethics Committee for Scotland (MREC/01/0/36) and
Local Research and Ethical Committees. Patients were only
selected for analysis if they initially responded to hormone
treatment (in the form of subcapsular bilateral orchidectomy or
maximum androgen blockade), but subsequently relapsed (two
consecutive rises in PSA greater than 10%) and had a pre- and
posthormone relapse tissue sample available for analysis.
Immunohistochemistry
All IHC was performed on 5mm, archival formalin-fixed, paraffin-
embedded prostate tumour sections on separate slides. Immuno-
histochemistry for PI3K (p110 catalytic subunit), Akt1–3,
phosphorylated Akt at threonine 473 (pAkt
473), mTOR, phos-
phorylated mTOR at serine 2448 (mTOR
2448) and phosphorylated
AR at serine 210 (pAR
210) were performed as follows: antigen
retrieval was performed using heat treatment under pressure in a
Tris EDTA buffer (5mM Trizma Base, 1mM EDTA, pH 8: Akt1–3
and pAR
210) or citrate buffer (PI3K and mTOR) for 5min or by
heating to 961C for 20min in citrate buffer (pAkt
308, pAkt
308 and
pmTOR
2448). Nonspecific background staining was blocked using
either 2.5% horse serum in TBS for 20min (PI3K and pAR
210),
in 1% casein for 10min (Akt1–3, mTOR and pmTOR
2448)o ri n
Serum Free Block (Dako A/S, Glostrup, Denmark) for 10min
(pAkt
473). Phosphatidylinositol 3-OH kinase (Cell Signalling
Technology, Beverly, MA, USA), Akt1–3 (Santa Cruz Biotechno-
logy Inc., Santa Cruz, CA, USA), pAkt
473 (Cell Signalling
Technology), mTOR (Santa Cruz Biotechnology Inc.), pmTOR
2448
(Cell Signalling Technology) and pAR
210 (Imgenex, San Diego, CA,
USA) antibodies were used at the following concentrations (1, 1, 2,
2, 4, 5, 2 and 50mgml
 1). Phosphorylated AR at serine 210 was
incubated for 1h at 251C and all other antibodies were incubated
overnight at 41C. For the mTOR antibody only, incubation with
rabbit anti-goat antibody (Dako A/S) (1:4000) for 1h at room
temperature was also required. Staining for PI3K, pAkt
308, pAkt
473,
mTOR and pmTOR
2448 was developed using EnVision plus kit
(Dako A/S) and staining for Akt1–3 and pAR
210 was developed
using LSAB kit (Dako A/S) and 3,3-diaminobenzidine tetra-
hydrochloride (DAB; Vector Laboratories, CA, USA). Nuclei were
counterstained with haematoxylin before mounting. A positive and
a negative control were included in each IHC run, negative
controls were incubated with an isotype-matched control antibody
at a concentration of 1mgml
 1. Positive control slides were breast
tissue known to express PI3K, Akt and mTor, BPH tissue known to
express AR and MCF-7 and LNCaP cell pellets. Antibody
specificity was confirmed by western blotting. In addition,
phosphorylated antibodies were confirmed to detect only the
phosphorylated forms using calf intestinal alkaline phosphatase to
destroy phosphorylated proteins. Two identical slides had IHC
performed on them, the only difference being that one was
previously treated with calf intestinal alkaline phosphatase, the
untreated slide expressed the phosphorylate protein and the
treated slide did not, this technique confirms that the antibody is
only detecting the phosphorylated form of the protein and not the
unphosphorylated form.
Tissue staining intensity was scored blind by two independent
observers using a weighted histoscore method (Fraser et al, 2003)
also known as the Hscore system (McCarty et al, 1986).
Histoscores were calculated from the sum of (1 % cells staining
weakly positive)þ(2 % cell staining moderately positive)þ
Table 1 Histoscore variation and comparison of staining intensity for hormone-sensitive and hormone-refractory tumours
HSPC (IQR) HRPC (IQR) P-value ICCC Histoscore units Fallers Risers
PI3Kc 100 (58–140) 100 (79–134) 0.875 0.85 60 23 23
Akt1m 0 (0–11) 0 (0–90) 0.798 0.88 30 14 13
Akt1c 75 (20–100) 70 (0–90) 0.488 0.82 55 20 13
Akt1n 0 (0–18) 0 (0–0) 0.110 0.95 21 19 9
Akt2 125 (100–185) 120 (98–165) 0.551 0.81 61 22 13
Akt3 50 (0–100) 60 (0–95) 0.619 0.84 48 20 30
pAkt
473m 40 (0–90) 33 (0–90) 0.988 0.90 58 22 23
pAkt
473c 88 (54–110) 80 (40–105) 0.671 0.89 49 25 23
pAkt
473n 0 (0–25) 0 (0–35) 0.465 0.93 40 15 18
pAR
210n 35 (0–85) 103 (50–169) o0.0001 0.93 52 8 42
mTORm 0 (0–20) 0 (0–10) 0.134 0.92 47 10 3
mTORc 43 (15–87) 40 (10–62) 0.123 0.83 31 35 23
pmTOR
2448m 0 (0–22) 0 (0–15) 0.330 0.95 33 14 8
pmTOR
2448c 61 (20–100) 40 (8–70) 0.044 0.91 45 33 23
pmTOR
2448n 0 (0–10) 0 (0–0) 0.575 0.90 19 3 6
Table 1 shows the median histoscore and interquartile range (IQR) for hormone-sensitive tumours (HSPCs) and hormone-refractory tumours (HRPCs) and the P-values of
HSPC histoscores compared to HRPC histoscores using a Wilcoxon signed-rank test. The median histoscore was the cutoff histoscore used to select for the separate subgroups
when defining high and low expressers. The interclass correlation coefficient (ICCC), which measures consistence between observers for each protein, is consistently higher than
0.7, which is classed as excellent. The mean difference in observer scores plus 2 s.d. is also shown as the number of histoscore units, that is, the cutoff in histoscore units used to
select for the separate subgroups, which is defined as a change in protein expression. The percentage of tumours that were defined as having a fall or rise in protein expression
(calculated using the number of histoscore units, which is defined as a change in expression) are also shown. ‘m’, ‘c’ and ‘n’ relates to protein location, m¼membrane,
c¼cytoplasm and n¼nucleus. ‘P’ before a protein indicates that the antibody detects phosphorylated protein, and the number following the protein represents the site of
phosphorylation.
Bold value represents statistical significance.
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s(3 % cells staining strongly positive) with a maximum of 300.
The interclass correlation coefficient (ICCC) for each protein was
calculated to confirm consistency between observers, and the mean
of the two observers’ scores were used for analysis. Changes in
staining between pre- and posthormone-refractory cases were
defined as an increase or decrease with the 95% confidence interval
(CI) for the difference in interobserver variation, which is the
mean difference between the histoscores that each observer assigns
for protein expression plus 2 s.d. Change in expression of PI3K,
Akt1–3, mTOR, pmTOR
2448 and pAR
210 are shown in Table 1.
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Figure 1 (A) shows the actual increase in histoscore units of the 42% of patients whose tumours exhibited an increase in pAR
210 expression in the
transition from hormone-sensitive to -refractory disease. (B and C) These images are of an actual pair of hormone-sensitive and -refractory tumours whose
expression increased by 150 histoscore units. Brown nuclear staining denotes pAR
210 expression. Magnification  400. (D) These images show examples of
a negative control, a tumour that was score with a histoscore in the range of 1–100, 101–200 or 201–300.
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sStatistical analysis
Interclass correlation coefficients were used to confirm consistency
between observers. Protein expression data were not normally
distributed and are shown as median and interquartile ranges.
Wilcoxon signed-rank tests were used to compare expression
between pre- and posthormone-refractory tumours. Survival
analyses were conducted using Kaplan–Meier method, and curves
were compared with the log-rank test. Hazard ratios (HRs) were
calculated using Cox regression analysis. Correlations between
members of the pathway were performed using a Spearman’s rank
test.
RESULTS
Patients
A total of 68 prostate cancer patients (diagnosed between 1984 and
2000) were included in this study with matched hormone-sensitive
(hormone-sensitive tissue was obtained from 26 patients by TRUS-
guided biopsy and the remaining 42 by TURP) and -refractory
prostate tumours (all obtained by TURP) available for analysis
(136 tumours in total). Patients in this cohort were diagnosed with
locally advanced (50) or metastatic prostate cancer (18) and
subsequently received surgery and androgen deprivation therapy
(26 subcapsular bilateral orchidectomy, 44 GnRH analogue and 2
had both). Forty-five of the sixty-eight patients also received
antiandrogen therapy, and this included all those who received
GnRH analogues. At initial diagnosis, the median age was 70
(66–74) years and 26% of patients had metastatic disease. The
median time to biochemical relapse was 2.32 (1.48–4.00) years,
and the percentage of patients with metastatic disease had
increased to 57%. Sixty-one patients (89.7%) died during follow-
up and median survival for these patients was 4.34 (2.94–6.63)
years. Seven patients were alive at last follow-up; the median time
of follow-up for all 68 patients was 4.34 (2.86–6.74) years.
Protein expression patterns
Akt1, pAkt
473 and pmTOR
2448 protein expression was observed in
the cell membrane, cytoplasm or nucleus. mTOR expression was
observed at the membrane and cytoplasm, and PI3K, Akt2 and
Akt3 expression was observed only in the cytoplasm. Nuclear
expression was observed for pAR
210 (Figure 1; Table 1). To assess
the level of agreement between observers, ICCCs were calculated
for each antibody at each location using SPSS; all ICCC values in
this study were 40.7 (which is classed as excellent) (Table 1).
Protein expression levels and changes in protein expression The
median expression levels for all proteins investigated were
calculated for hormone-sensitive and -refractory tumours
(Table 1). The Wilcoxon signed-rank test was used to compare
expression levels in the hormone-sensitive tumours compared to
hormone-refractory tumours. Using this method, only pAR
210
significantly increased with the development of hormone-
refractory disease. The median expression of pAR
210 in hormone-
sensitive tumours was 35 (0–85) increasing to 103 (50–169) in
hormone-refractory tumours (Po0.0001) (Table 1). This
demonstrates an increase in AR phosphorylation at the Akt
consensus site in the transition from hormone-sensitive to -
refractory disease.
The nature of our cohort, however (matched hormone-sensitive
and -refractory tumours for each patient), allowed us to establish if
there was a change in protein expression levels in the transition
from hormone-sensitive to -refractory disease for each individual
patient. By examining the change in protein expression for each
patient, we were able to create subgroups of patients whose
tumours exhibited either a fall or rise in protein expression for all
proteins investigated (Table 1). Using this technique, it was
observed that 42% of patients investigated in this study had an
increase in pAR
210 expression in the transition from hormone-
sensitive to -refractory disease (Figure 1).
Are protein expression levels in hormone-sensitive or -refractory
tumours associated with relapse or survival? When expression
levels of each protein investigated in the hormone-sensitive
tumours were divided into high or low expression (levels above
or below the median), none of the proteins investigated were
associated with time to relapse or disease-specific survival. The
histoscores used as a cutoff for each analysis was the median
histoscore; the median histoscore for each protein investigated is
given in Table 1.
When expression levels of each protein investigated in the
hormone-refractory tumours were divided into high or low
expression (levels above or below the median), only pAR
210 was
associated with quicker time to death from relapse (Figure 2A;
P¼0.003, HR¼2.85 (95% CI: 1.38–5.87)) and quicker disease-
specific survival (Figure 2B; P¼0.0136, HR¼2.33 (95% CI: 1.16–
4.66). Median survival from time of relapse for those patients with
tumours that expressed low levels of pAR
210 was 3.42 (IQR: 2.82–
4.02) years compared to 1.40 (IQR: 0.85–1.95) years for those who
had tumours that expressed high levels of pAR
210, and the median
disease-specific survival for those patients with tumours that
expressed low levels of pAR
210 was 8.57 (IQR: 5.41–11.73) years
compared to 5.82 (IQR: 3.18–8.46) years for those who had
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Figure 2 (A) Kaplan–Meier plot demonstrates that those patients
whose hormone-refractory tumour has high pAR
210 nuclear expression
(broken line) have shorter time to disease-specific death from time of
biochemical relapse than those patients whose hormone-refractory tumour
has low pAR
210 nuclear expression (solid line) (P¼0.003). (B) Kaplan–
Meier plot demonstrates that those patients whose hormone-refractory
tumour has high pAR
210 nuclear expression (broken line) have shorter
disease-specific survival than those patients whose hormone-refractory
tumour has low pAR
210 nuclear expression (solid line) (P¼0.014).
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stumours that expressed high levels of pAR
210. This represents a
survival difference of almost 3 years for patients expressing high
levels of pAR
210 in their hormone-refractory tumour.
Are changes in protein expression in the transition from hormone-
sensitive to -refractory disease associated with relapse or survival?
When expression levels in hormone-sensitive or -refractory
tumours were used to investigate a link between activation of the
PI3K pathway and development of hormone-refractory disease,
only AR phosphorylated at the Akt consensus site was associated
with survival. However due to the nature of the current cohort, we
were also able to investigate if those patients whose tumours
exhibit an increase or rise in expression of members of the
pathway in the transition from hormone-sensitive to -refractory
disease were more likely to relapse or die quicker. The cutoff
histoscore selected to separate subgroups of patients is displayed
in Table 1. Using this method, an increase in PI3K (Figure 3A;
P¼0.014, HR¼2.11 (95% CI: 1.14–3.91)) was associated with
quicker time to relapse. The median time to relapse for those
patients whose tumours have a decrease or no change in PI3K
expression was 2.57 (IQR: 1.74–3.40) years compared to 1.36 (IQR:
1.20–2.72) years for those patients whose tumours had an increase
in PI3K expression.
A rise in pAR
210 (Figure 3B; Po0.0001, HR¼4.18 (95% CI:
1.99–8.74)) was associated with quicker time to death from
relapse, the median survival from biochemical relapse for those
patients whose tumours had a decrease or no change in pAR
210
expression was 3.46 (IQR: 1.39–5.53) years compared to 1.25 (IQR:
0.83–1.67) years for those patients whose tumours had an increase
in pAR
210 expression.
A rise in pAkt
473 (Figure 3C; P¼0.0019, HR¼2.89 (95% CI:
1.43–5.8)) and pAR
210 (Figure 3D; P¼0.0015, HR¼2.86 (95%
CI: 1.45–5.67)) were associated with shorter disease-specific
survival. The median survival from diagnosis for those patients
whose tumours had no change or decrease in pAkt
473 was 6.68
(IQR: 6.22–7.14) years compare to 4.15 (IQR: 2.65–65) years for
those patients whose tumours had an increase in pAkt
473
expression, and the median survival from diagnosis for those
patients whose tumours had a decrease or no change in expression
of pAR
210 was 6.95 (IQR: 4.07–9.83) years compared to 4.36 (IQR:
1.67–7.10) years for those patients whose tumours had an increase
in pAR
210 expression. Therefore, an increase in expression in the
transition from hormone-sensitive to -refractory disease of
phosphorylated members of this pathway was associated with a
reduction in median survival of 2.5–3 years.
Correlations between active members of the pathway In
hormone-sensitive tumours, expression levels of the phosphory-
lated proteins did not correlate; no correlation was made between
Akt activation and AR phosphorylation (Figure 4A). However, in
the hormone-refractory tumours pAkt
473 correlated with pAR
210
(rs¼0.711, Po0.001) (Figure 4B) and pmTOR
2448 (rs¼0.489,
P¼0.003). Table 2 shows the individual histoscores for pAkt and
PI3K in patients with and without pAR
210 increases; no changes in
median expression levels was observed between the groups.
DISCUSSION
Cell line studies demonstrate that the PI3K cascade may influence
the development of HRPC, suggesting this pathway may provide a
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Figure 3 (A) Kaplan–Meier plot demonstrates that those patients whose tumours exhibit a rise in PI3K expression (broken line) relapse quicker than
those patients whose tumours exhibit no change or a fall in PI3K expression (solid line). (B) Kaplan–Meier plot demonstrates that those patients whose
tumours exhibit a rise in pAR
210 expression (broken line) have shorter time to disease-specific death from time of biochemical relapse than those patients
whose tumours exhibit no change or a fall in pAR
210 expression (solid line). (C) Kaplan–Meier plot demonstrates that those patients whose tumours exhibit
a rise in pAkt
473 cytoplasmic expression (broken line) have shorter time to disease-specific death than those patients whose tumours exhibit no change or a
fall in pAkt
473 expression (solid line). (D) Kaplan–Meier plot demonstrates that those patients whose tumours exhibit a rise in pAR
210 expression (broken
line) have shorter time to disease-specific death than those patients whose tumours exhibit no change or a fall in pAR
210 expression (solid line).
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this into the clinic, we are required to provide evidence that this
pathway is upregulated in the development of clinical HRPC and
also identify what proteins would make the best targets and most
effectively identify patients suitable for therapy.
It is well established in the literature that there is a link between
Akt activation and development of HRPC. Cell line work
demonstrates that Akt activity increases during androgen ablation
to stimulate cell growth and survival when androgen reliance is
weaker, and therefore promote development of HRPC (Gao et al,
2003; Ghosh et al, 2003; Lin et al, 2003). Work using human
prostate tissue confirms that pAkt
473 is expressed in PIN and
invasive prostate cancer, and staining intensity positively corre-
lated with PSA levels and Gleason grades (Ghosh et al, 2003;
Altomare and Testa, 2005; Majumder and Sellers, 2005). In
addition, a large study of 640 radical prostatectomy specimens
demonstrated that high levels of pAkt was predictive of
biochemical recurrence (Ayala et al, 2003). Although in our
current cohort we did not observe a significant association with
pAkt
473 and biochemical recurrence (pAkt
473; P¼0.151, results not
shown), the Kaplan–Meier curves did separate and the difference
in the median time to biochemical recurrence in the two groups
was 1.8 year compared to 2.4 years, suggesting that significance
might have been meet if a larger cohort had been used. As the
previous study was conducted on a cohort of 640 patient samples
and our cohort contained only 68 patients, we performed a power
calculation to assess what cohort size would have been required.
This calculation suggested that a cohort of 200 patients would have
been sufficient to reach significance. It is therefore not surprising
that a significant result was achieved on a cohort of 640 samples.
However the design of our study was to mirror the cell line
experiments and investigate if changes in protein expression of
members of the PI3K/Akt cascade were involved in the transition
from hormone-sensitive to -refractory disease; therefore, we felt
that it was not necessary to increase that cohort size. The strength
of this study was the use of the paired samples, by doing so we
observed that an increase in expression of multiple members of the
pathway was linked to time to recurrence and disease-specific
survival. In addition, if only primary tumours had been used, we
would not have observed that pAR
210 was linked to survival, as
marked expression was only observe in hormone-refractory
tumours. In the current study, we observe that an increase in
pAkt
473 expression, fully activated Akt and an increase in pAR
210
was associated with decreased survival. Providing further evidence
that activation of the PI3K/Akt cascade is associated with
development of HRPC.
Cell line data suggest that phosphorylation of AR by Akt at
serine 210 results in an increase in AR translational activity when
androgen levels are low, and, in addition, activated Akt, over a
longer period, has been demonstrated to upregulated AR expres-
sion in LNCaP cells (Manin et al, 2002; Yang et al, 2005). The
impact of both these actions of Akt on the AR will serve to increase
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Figure 4 Scatter plots of pAkt
473 histoscore compared to pAR
210 histoscore, (A) is in the hormone-sensitive tissue and no significant correlation was
observed (P¼0.061, correlation coefficient 0.251); however, (B) is in the hormone-refractory tissue, where a significant correlation was observed (Po0.001
and correlation coefficient 0.711).
Table 2 Histoscores of pAkt and PI3K and comparison of staining
intensity between patients with or without an increase in pAR
210
expression
Group 1 Group 2
HS HR HS HR
PAkt PI3K pAkt PI3K pAkt PI3K pAkt PI3K
0 80 0 70 0 30 110 95
0 100 105 90 70 110 NA 180
90 160 0 60 50 80 NA 105
0 260 0 100 55 50 100 40
NA NA NA NA 105 105 NA 160
130 140 55 60 90 105 180 80
90 20 125 90 0 130 40 90
NA NA 120 160 25 30 140 100
50 15 NA 100 75 190 2.5 280
130 70 105 0 110 200 55 35
50 53.75 60 100 85 25 150 10
110 200 0 132.5 100 40 5 180
NA NA NA NA 100 80 117.5 130
135 130 40 140 80 25 90 105
20 100 102.5 170 95 140 0 62.5
130 105 50 120 97.5 100 75 90
NA 100 NA 30 72.5 115 105 100
100 0 5 50 0 0 110 70
110 180 80 195 100 0 NA NA
100 100 20 200 75 110 120 115
100 195 100 165 65 80 185 100
162.5 190 90 100 0 15 90 100
180 210 100 160 NA NA NA NA
NA 90 NA 120 137.5 170 35 105
165 0 40 100 0 90 75 75
60 40 5 25 NA 200 NA 137.5
85 190 80 0 160 200 135 150
25 115 100 100 125 170 0 190
90 100 155 80 220 200 0 150
35 100 70 25 120 120 NA 160
70 120 40 100 72.5 100 100 80
85 NA 60 NA 75 40 130 0
NA 200 NA 100 120 80 150 0
90 100 60 100 NA NA NA NA
NA=not available. Table 2 shows the histoscore for cytoplasmic phosphorylated Akt
and PI3K in hormone-sensitive tumours (HS) and hormone-refractory tumours (HR).
Group 1 represents those patients with no increase in phosphorylated AR expression,
and group 2 represents those patients with an increase in phosphorylated AR
expression in the transition from hormone-sensitive to hormone-refractory disease.
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AR-regulated genes even when androgens levels are very low,
similar to those experienced during chemical or surgical castra-
tion. This therefore provides a mechanism for the development of
HRPC. In the current cohort, HRPCs express significantly higher
levels of pAR
210 compared to hormone-sensitive tumours; the
median histoscore of refractory tumours is 103 histoscore units
compared to 35 histoscore units for sensitive tumours,
P¼o0.0001. Approximately 42% of patients have an increase in
pAR
210 expression, and these patients have a significantly shorter
survival period than those with no increase in expression. In
addition, expression levels of pAR
210 and AR strongly correlate
with pAkt
473 expression levels only in the refractory tumours,
suggesting that it is only when androgen levels are low that this
pathway is activated. These results provide additional evidence
that the PI3K/Akt pathway is upregulated during development of
HRPC, resulting in phosphorylation of the AR and sensitisation to
circulating adrenal androgens. Cell line studies demonstrate that
this occurs in vitro; however, the current data demonstrate for the
first time that this may be one possible mechanism allowing
development of HRPC in the clinical setting (Figure 5).
The protein mTOR is also downstream of Akt and was also
investigated in this study as it has previously been to HRPC (Bubley
et al, 2003). Akt can phosphorylate mTOR directly at threonine 2446
and serine 2448, but can also activate mTOR indirectly via
phosphorylation of TSC2 (Majumder and Sellers, 2005). In the
current cohort, pAkt
473 expression correlates with pmTOR
2448
expression; however, expression levels or changes in expression
levels of pmTOR
2448 do not correlate with any clinical parameters in
our cohort. This suggests that mTOR may not be involved in the
development of HRPC. This was surprising as stimulation of mTOR
ultimately results in increase protein synthesis and enhances
translation of proteins involved in growth control via turning off
4EBP and activating S6Kinase. Although Akt has been demonstrated
to phosphorylate mTOR directly, the role of these phosphorylation
sites remains unclear. Phosphorylation of mTOR by Akt at serine
2448 might not correlate with mTOR activation, therefore,
pmTOR
2448 may not necessary be involved with the development
of HRPC, and a more appropriate marker of mTOR activation could
be S6Kinase (Ruggero and Sonenberg, 2005).
In summary, they current study demonstrates a role for the
PI3K/Akt/AR pathway in the development of HRPC; however, now
that drugs are being developed to target specific components of
pathways, it is necessary to identify the proteins in the individual
pathways that would make the most appropriate targets. Results
from the current study suggest that a larger portion of tumours
would respond to drugs targeting Akt activation in contrast to
PI3K or PTEN. Methods currently being explored for inhibition of
Akt activation include Akt antibodies, similar to humanised
trastuzamab (Herceptin), ATP-competitive inhibitors and PDK1
inhibitors (Cheng et al, 2005). In addition to Akt being the
appropriate target for therapy, Akt in combination with pAR
210
might be the appropriate marker for identifying patients most
likely to respond to drugs that target Akt activation. Phosphory-
lation of Akt and AR are clearly linked with decreased survival,
those patients who have an increase in pAtk
473 and/or pAR
210 have
median overall survival period of 3.98 years compared to 6.68
years, this is a survival difference of almost 3 years, and
approximately 50% of the patients in our study have an increase
in pAkt
473 and/or pAR
210 expression, suggesting that the majority
of patients likely to respond to Akt inhibition will be identified by
these markers. This study emphasises the need for a rational
approach for new drug design, and the progress already made in
breast cancer demonstrates the effectiveness of such an approach.
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